Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Recover your password.
A password will be e-mailed to you.
Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
Paris, February 3, 2023
Q4 2022 sales growth of 2.6% at CER and business EPS(1) growth of 17.4% at CER
Full-year 2022 delivered 7.0% sales growth and 17.1% business EPS growth at CER
Progress on Corporate Social Responsibility strategy in Q4
Key R&D milestones and regulatory achievements in Q4
Full-year 2023 business EPS guidance
Sanofi Chief Executive Officer, Paul Hudson, commented:
“We closed 2022, marking the successful execution of the first chapter of our 6-year ‘Play to Win’ strategy. Specialty Care delivered the highest sales among our businesses. Dupixent® and Vaccines continue to be our leading growth drivers. We are particularly proud of the progress we made in R&D transformation with multiple approvals of transformative medicines and new product launches across Specialty Care. At the same time, we keep delivering strong proof points of our improved financial performance underpinned by the achievement of the 30% BOI margin. Moving to the next chapter of our strategy, we are looking forward to the planned launches of Altuviiio® and Beyfortus® as well as key pivotal readouts, including the COPD indication for Dupixent®. With the view on the expected entrants of generic competition for Aubagio® in the coming months, we remain confident in our outstanding commercial capabilities, including the ambition to reach sales of 10 billion euros for Dupixent® in 2023, enabling us to guide to low single-digit EPS growth for the year.”
Q4 2022 | Change | Change at CER |
2022 | Change | Change at CER |
|
IFRS net sales reported | €10,725m | +7.3% | +2.6% | €42,997m | +13.9% | +7.0% |
IFRS net income reported | €1,460m | +29.1% | _ | €6,720m | +8.0% | — |
IFRS EPS reported | €1.16 | +28.9% | _ | €5.37 | +8.0% | — |
Free cash flow(3) | €2,546m | +0.2% | _ | €8,483m | +4.8% | — |
Business operating income | €2,724m | +20.7% | +15.0% | €13,040m | +21.7% | +13.3% |
Business net income(1) | €2,141m | +23.8% | +17.6% | €10,341m | +25.9% | +17.0% |
Business EPS(1) | €1.71 | +23.9% | +17.4% | €8.26 | +25.9% | +17.1% |
Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (definition in Appendix 9). The consolidated income statement for Q4 2022 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) 2022 business EPS was €8.26; (3) Free cash flow is a non-GAAP financial measure (definition in Appendix 9).
Get real time updates directly on you device, subscribe now.